Navigation Links
VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation
Date:6/4/2009

nce they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to:

        -- our ability to borrow additional amounts under the loan from Bay
           City Capital, which is subject to the discretion of Bay City
           Capital;
        -- our ability to obtain necessary financing in the near term,
           including amounts necessary to repay the loan from Bay City Capital
           by the September 14, 2009 maturity date (or earlier if certain
           repayment acceleration provisions are triggered);
        -- our ability to control our operating expenses;
        -- our ability to comply with covenants included in the loan from Bay
           City Capital;
        -- our ability to maintain the listing of our common stock on NASDAQ;
        -- our failure to timely recruit and enroll patients for the FDG-PET
           clinical trial, as well as any future clinical trial;
        -- our failure to obtain sufficient data from enrolled patients that
           can be used to evaluate VIA-2291, thereby impairing the validity or
           statistical significance of our clinical trials;
        -- our ability to successfully complete our clinical trials of
           VIA-2291 on expected timetables and the outcomes of such clinical
           trials;
        -- complexities in designing and implementing cardiovascular clinical
           trials using histological examinations, measurement of biomarkers,
           medical imaging and atherosclerotic plaque bioassays;
        -- the results of our clinical trials, including without limitation,
           with respect to the safety and efficacy of VIA-2291;
        -- if the results of
'/>"/>
SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
2. Amylin Pharmaceuticals to Present at Goldman Sachs Annual Global Health Care Conference
3. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
4. Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis
5. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
6. Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
7. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
8. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
9. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
10. Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009
11. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... interdisciplinary team of researchers led by Northeastern University ... precise inter-nanotube junctions and a variety of nanocarbon ... facile and easily scalable, which will allow the ... networks for use in applications ranging from electronic ... from cars to sports equipment. , Their findings ...
(Date:9/15/2014)... , Sept. 15, 2014  iVinci Health LLC, the ... Patient Revenue Management system, branded as VisitPay®, has successfully ... announced the launch of a new extension to VisitPay® ... an easy and convenient way for patients to manage ... owed by them and their families. The ...
(Date:9/15/2014)... CA (PRWEB) September 15, 2014 ... term implantable silicones for the medical device and ... silicone gel for the implantable medical device market. ... unique crosslink technology delivering a silicone gel with ... The Dual Matrix technology consists of two crosslinked ...
(Date:9/15/2014)... septiembre de 2014 La segunda anual International ... 12 al 18 de octubre. Como iniciativa conjunta de la ... compañías miembro s, la IPAW se ha diseñado para: ... a la colección de fuentes de plasma , Reconocimiento ... y mejorar las vidas , Aumento del conocimiento sobre ...
Breaking Biology Technology:Northeastern University Researchers Develop Novel Method for Working with Nanotubes 2iVinci Health Raises $5M to Fuel National Expansion, Announces Launch of Personal Finance Portal for Healthcare 2iVinci Health Raises $5M to Fuel National Expansion, Announces Launch of Personal Finance Portal for Healthcare 3Applied Silicone Launches Silicone Gel System with Dual Matrix Technology 2La International Plasma Awareness Week será una celebración para los donantes 2La International Plasma Awareness Week será una celebración para los donantes 3
... 2008 at 9:00 a.m. Eastern ... ... ALSE ) today reports operational and,financial results for the quarter ended ... http://www.newscom.com/cgi-bin/prnh/20080813/NEW056LOGO ), "We are encouraged by the progress we ...
... Named Contract Manufacturer of Choice, Based on Its ... Based on its recent,analysis of the pharmaceutical ... BioPharma Solutions (BPS) with the 2008 North,American Frost ... Award at,the 2008 Excellence in Healthcare Innovation Awards ...
... Novavax uses strategies to create vaccines for avian flu ... genetically-engineered virus-like particles (VLPs), ROCKVILLE, Md., ... today that its strategy for treating avian flu,through genetically-engineered ... at Cleveland Clinic 6th Annual Medical Innovation,Summit., Novavax, ...
Cached Biology Technology:Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 2Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 3Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 4Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 5Frost & Sullivan Awards Baxter's BioPharma Solutions Business the 2008 North American Customer Service Leadership of the Year Award 2Frost & Sullivan Awards Baxter's BioPharma Solutions Business the 2008 North American Customer Service Leadership of the Year Award 3Cleveland Clinic Recognizes New Strategies for Creating Vaccines for Avian Flu as a Top Ten Medical Innovation for 2009 2Cleveland Clinic Recognizes New Strategies for Creating Vaccines for Avian Flu as a Top Ten Medical Innovation for 2009 3Cleveland Clinic Recognizes New Strategies for Creating Vaccines for Avian Flu as a Top Ten Medical Innovation for 2009 4
(Date:9/15/2014)... need for vitamin E and how much is enough, ... of this essential micronutrient are especially critical for the ... may become pregnant. , A lifelong proper intake of ... complicated by the fact that this nutrient is one ... It has been estimated that only a tiny fraction ...
(Date:9/12/2014)... , September 12, 2014 ... http://www.researchandmarkets.com/research/trs4c7/global ) has announced the addition of ... 2014" report to their offering. ,     ... Report 2014 is a professional and in-depth ... global fingerprint lock industry. , ,The report ...
(Date:9/12/2014)... of New York biologist Mike Hickerson, a team of international ... so many species of birds ended up in the Neotropics, ... the southernmost tip of South America. It is home to ... has beenhow did this extraordinary bird diversity originate?" said Dr. ... published in the journal Nature this week and ...
Breaking Biology News(10 mins):Vitamin E intake critical during 'the first 1,000 days' 2Vitamin E intake critical during 'the first 1,000 days' 3Global Fingerprint Lock Industry Report 2014 2
... of Biologists is pleased to announce BIOLOGY OPEN (BiO), ... research across all aspects of the biological sciences including ... journal aims to provide rapid publication for peer reviewed, ... fields. BIOLOGY OPEN will address some big issues ...
... a big effect on their life. Some people are ... which can be detrimental to their health and wellbeing. ... , A new study led by Dr Kathryn ... York has added important experimental evidence showing that animal ...
... fish, one from a Caribbean island and one from the Yucatan ... known in any organism, according to a new UC Davis study. ... Venezuela -- and they are all pretty much the same, said ... with Peter Wainwright, a professor of evolution and ecology at UC ...
Cached Biology News:Announcing BIOLOGY OPEN from the Company of Biologists 2Animals have personalities, too 2'Explosive' evolution in pupfish 2
... Single Cell Whole Genome Amplification Kit ... random fragmentation of genomic DNA and ... to PCR-amplifiable library molecules flanked by ... by PCR amplification of the library ...
Mouse monoclonal antibody to QARS - glutaminyl-tRNA synthetase...
Rabbit Anti-Mouse Ym1 Polyclonal Antibody,...
From formula-fed bovine calves Sterile, Cell culture tested...
Biology Products: